NCT01474941View on ClinicalTrials.gov

A Study Of PF-04620110 As A Modified-Release Formulation In Healthy Overweight Or Obese Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions
Healthy
Interventions
DRUG

PF-04620110 or Placebo

Multiple oral doses of 5 mg PF-04620110 as a modified-release formulation or placebo once daily for 2 weeks

DRUG

PF-04620110 or Placebo

Multiple oral doses of 5 mg PF-04620110 as a modified-release formulation or placebo twice daily for 2 weeks

DRUG

PF-04620110 or Placebo

Repeat Arm 1 or Arm 2

Trial Locations (1)

B-1070

Pfizer Investigational Site, Brussels

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01474941 - A Study Of PF-04620110 As A Modified-Release Formulation In Healthy Overweight Or Obese Subjects | Biotech Hunter | Biotech Hunter